Document:

Exhibit
4.1

 

Form
of Representative’s Warrant Agreement

 

THE
REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR
HYPOTHECATE THIS PURCHASE WARRANT OR BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT OR CALL TRANSACTION THAT WOULD
RESULT IN THE EFFECTIVE ECONOMIC DISPOSITION OF THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED FOR A PERIOD OF ONE HUNDRED EIGHTY
DAYS FOLLOWING THE EFFECTIVE DATE (DEFINED BELOW) TO ANYONE OTHER THAN (I) THINKEQUITY, A DIVISION OF FORDHAM FINANCIAL MANAGEMENT,
INC., OR AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF THINKEQUITY,
A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC., OR OF ANY SUCH UNDERWRITER OR SELECTED DEALER.

 

THIS
PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO [________________] [DATE THAT IS [180 DAYS] FROM THE EFFECTIVE DATE OF THE OFFERING].
VOID AFTER 5:00 P.M., EASTERN TIME, [___________________] [DATE THAT IS FIVE YEARS FROM THE EFFECTIVE DATE OF THE OFFERING].

 

WARRANT
TO PURCHASE COMMON STOCK

 

SAVE
FOODS, INC.

 

	Warrant
Shares: _______1	 Initial
    Exercise Date: ______, 2021

 

THIS
WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, _____________ or its assigns
(the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after ____, 2021, which is one hundred eighty (180) days following the Effective Date (the “Initial
Exercise Date”) and, in accordance with FINRA Rule 5110(g)(8)(A), prior to at 5:00 p.m. (New York time) on the date
that is five (5) years following the Effective Date (the “Termination Date”) but not thereafter, to subscribe
for and purchase from Save Foods, Inc., a Delaware corporation (the “Company”), up to ______1 shares
of Common Stock, par value $0.0001 per share (the “Common Stock”), of the Company (the “Warrant Shares”),
as subject to adjustment hereunder. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section 2(b).

 

Section
1. Definitions. In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings
indicated in this Section 1:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Business
Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; provided that banks shall not be deemed to be authorized or obligated to be closed due to
a “shelter in place,” “non-essential employee” or similar closure of physical branch locations at the
direction of any governmental authority if such banks’ electronic funds transfer systems (including for wire transfers)
are open for use by customers on such day.

 

 

1Total
equals 5% of the aggregate number of Firm Shares issued and sold in the Offering.

 

    	1

    	 

    

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Effective
Date” means the effective date of the registration statement on Form S-1 (File No. 333-[___]) including any related
prospectus or prospectuses, for the registration of the Company’s Common Stock under the Securities Act, that the Company
has filed with the Commission.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Trading
Day” means a day on which the New York Stock Exchange is open for trading.

 

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market,
or the New York Stock Exchange (or any successors to any of the foregoing).

 

“Underwriting
Agreement” means that certain Underwriting Agreement, dated as of [____], 2021, by and between, the Company and ThinkEquity,
a division of Fordham Financial Management, Inc., as representatives of the underwriters set forth therein.

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the
volume weighted average price of a share of Common Stock for such date (or the nearest preceding date) on the OTCQB or OTCQX as
applicable, (c) if Common Stock is not then listed or quoted for trading on the OTCQB or OTCQX and if prices for Common Stock
are then reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d) in all other cases,
the fair market value of the Common Stock as determined by an independent appraiser selected in good faith by the Holder and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

    	2

    	 

    

 

Section
2. Exercise.

 

a)
Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after
the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of
the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books
of the Company) of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise Form annexed hereto. Within
two (2) Trading Days following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank
unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice
of Exercise form be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant
has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within five
(5) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting
in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder
and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company
shall deliver any objection to any Notice of Exercise Form within two (2) Business Days of receipt of such notice. The Holder
and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any
given time may be less than the amount stated on the face hereof.

 

b)
Exercise Price. The exercise price per share of the Common Stock under this Warrant shall be $_______2,
subject to adjustment hereunder (the “Exercise Price”).

 

c)
Cashless Exercise. If at any time on or after the Initial Exercise Date, there is no effective registration statement registering,
or the prospectus contained therein is not available for the issuance of the Warrant Shares, then in lieu of exercising this Warrant
by delivering the aggregate Exercise Price by wire transfer or cashier’s check, at the election of the Holder this Warrant
may also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall
be entitled to receive the number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

	 	(A) =	as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading hours” on such Trading Day;

 

 

2
125% of the public offering price per share of Common Stock issued and sold in the offering.

 

    	3

    	 

    

 

	 	(B) =	the Exercise Price of this Warrant, as adjusted hereunder; and
	 	 	 
	 	(X) =	the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

 

If
Warrant Shares are issued in such a “cashless exercise,” the parties acknowledge and agree that in accordance with
Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised,
and the holding period of the Warrants being exercised may be tacked on to the holding period of the Warrant Shares. The Company
agrees not to take any position contrary to this Section 2(c).

 

Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise
pursuant to this Section 2(c).

 

d)
Mechanics of Exercise.

 

i.
Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted
by its transfer agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with
The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company
is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the
Warrant Shares to or resale of the Warrant Shares by Holder, or (B) the Warrant Shares are eligible for resale by the Holder without
volume or manner-of-sale limitations pursuant to Rule 144 and, in either case, the Warrant Shares have been sold by the Holder
prior to the Warrant Share Delivery Date (as defined below), and otherwise by physical delivery of a certificate, registered in
the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder
is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is two
(2) Trading Days after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery
Date”), provided that the Company shall not be obligated to deliver the Warrant Shares hereunder unless the Company
has received the aggregate Exercise Price on or before the Warrant Shares Delivery Date. If the Warrant Shares can be delivered
via DWAC, the transfer agent shall have received from the Company, at the expense of the Company, any legal opinions or other
documentation required by it to deliver such Warrant Shares without legend (subject to receipt by the Company of reasonable back
up documentation from the Holder, including with respect to affiliate status) and, if applicable and requested by the Company
prior to the Warrant Share Delivery Date, the transfer agent shall have received from the Holder a confirmation of sale of the
Warrant Shares (provided the requirement of the Holder to provide a confirmation as to the sale of Warrant Shares shall not be
applicable to the issuance of unlegended Warrant Shares upon a cashless exercise of this Warrant if the Warrant Shares are then
eligible for resale pursuant to Rule 144(b)(1)). The Warrant Shares shall be deemed to have been issued, and Holder or any other
person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as
of the date the Warrant has been exercised, with payment to the Company of the Exercise Price (or by cashless exercise, if permitted)
and all taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi) prior to the issuance of such shares, having
been paid. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by
the second Trading Day following the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated
damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock
on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading
Day after such liquidated damages begin to accrue) for each Trading Day after the second Trading Day following such Warrant Share
Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise.

 

    	4

    	 

    

 

ii.
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder
a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which
new Warrant shall in all other respects be identical with this Warrant.

 

iii.
Rescission Rights. If the Company fails to cause its transfer agent to deliver to the Holder the Warrant Shares pursuant
to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise; provided,
however, that the Holder shall be required to return any Warrant Shares or Common Stock subject to any such rescinded exercise
notice concurrently with the return to Holder of the aggregate Exercise Price paid to the Company for such Warrant Shares and
the restoration of Holder’s right to acquire such Warrant Shares pursuant to this Warrant (including, issuance of a replacement
warrant certificate evidencing such restored right).

 

iv.
Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available
to the Holder, if the Company fails to cause its transfer agent to transmit to the Holder the Warrant Shares pursuant to an exercise
on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open
market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in
satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying
(1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue
times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored
(in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would
have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder
purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice
indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount
of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law
or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s
failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

    	5

    	 

    

 

v.
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.

 

vi.
Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid
by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed
by the Holder; provided, however, that in the event that Warrant Shares are to be issued in a name other than the
name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly
executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for
any transfer tax incidental thereto. The Company shall pay all transfer agent fees required for same-day processing of any Notice
of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions)
required for same-day electronic delivery of the Warrant Shares.

 

vii.
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.

 

viii.
Signature. This Section 2 and the exercise form attached hereto set forth the totality of the procedures required of the
Holder in order to exercise this Purchase Warrant. Without limiting the preceding sentences, no ink-original exercise form shall
be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any exercise form be required in
order to exercise this Purchase Warrant. No additional legal opinion, other information or instructions shall be required of the
Holder to exercise this Purchase Warrant. The Company shall honor exercises of this Purchase Warrant and shall deliver Shares
underlying this Purchase Warrant in accordance with the terms, conditions and time periods set forth herein.

 

    	6

    	 

    

 

e)
Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not
have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect
to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would beneficially
own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of
shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock
issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of
shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially
owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any
other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on
conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged
by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of
the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall
be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and
of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group
status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a
Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic
or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a
more recent written notice by the Company or the Company’s transfer agent setting forth the number of shares of Common Stock
outstanding. Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm orally and in writing
to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock
shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by
the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial
Ownership Limitation” shall be 9.99% of the number of shares of the Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company,
may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership
Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to
the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e)
shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day
after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner
otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which
may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to
a successor holder of this Warrant.

 

    	7

    	 

    

 

Section
3. Certain Adjustments.

 

a)
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a)
shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.
For the purposes of clarification, the Exercise Price of this Warrant will not be adjusted in the event that the Company or any
Subsidiary thereof, as applicable, sells or grants any option to purchase, or sell or grant any right to reprice, or otherwise
dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any Common Stock or Common
Stock Equivalents, at an effective price per share less than the Exercise Price then in effect.

 

b)
[RESERVED]

 

c)
Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company
grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata
to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will
be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could
have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before
the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase
Rights (provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result
in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase
Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent)
and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

    	8

    	 

    

 

d)
Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend
(other than cash dividends) or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common
Stock, by way of return of capital or otherwise (including, without limitation, any distribution of shares or other securities,
property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other
similar transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in each such
case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated
therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before
the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders
of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, to
the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial
ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the
Holder exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised
at the time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until
the Holder has exercised this Warrant.

 

e)
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of
the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is
effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in
one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common
Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making
or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would
have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the
Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock
of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
(the “Alternate Consideration”) receivable by holders of Common Stock as a result of such Fundamental Transaction
for each share of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without
regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination
of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion
the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon
any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the
obligations of the Company under this Warrant in accordance with the provisions of this Section 3(e) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such
Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is
exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to
the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise
of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder
to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental
Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being
for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction),
and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction,
the provisions of this Warrant referring to the “Company” shall refer instead to the Successor Entity), and may exercise
every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect
as if such Successor Entity had been named as the Company herein.

 

f)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as
of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

g)
Notice to Holder.

 

i.
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the
Company shall promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

    	9

    	 

    

 

ii.
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever
form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or
purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall
be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a
party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby
the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed
a notice to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days
prior to the applicable record or effective date hereinafter specified, stating (x) the date on which a record is to be taken
for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as
of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants
are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is
expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall
be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to provide such notice or any defect therein
shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided
hereunder constitutes, or contains, material, non-public information regarding the Company or any of its Subsidiaries, the Company
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled
to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering
such notice except as may otherwise be expressly set forth herein.

 

Section
4. Transfer of Warrant.

 

a)
Transferability. Pursuant to FINRA Rule 5110(e)(1), neither this Warrant nor any Warrant Shares issued upon exercise of
this Warrant shall be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative,
put, or call transaction that would result in the effective economic disposition of the securities by any person for a period
of 180 days immediately following the date of effectiveness or commencement of sales of the offering pursuant to which this Warrant
is being issued, except the transfer of any security:

 

	 	i.	by
    operation of law or by reason of reorganization of the Company;
	 	 	 
	 	ii.	to
    any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred
    remain subject to the lock-up restriction in this Section 4(a) for the remainder of the time period;
	 	 	 
	 	iii.	if
    the aggregate amount of securities of the Company held by the Holder or related person do not exceed 1% of the securities
    being offered;
	 	 	 
	 	iv.	that
    is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member
    manages or otherwise directs investments by the fund, and participating members in the aggregate do not own more than 10%
    of the equity in the fund; or

 

    	10

    	 

    

 

	 	v.	the
    exercise or conversion of any security, if all securities received remain subject to the lock-up restriction in this Section
    4(a) for the remainder of the time period.

 

Subject
to the foregoing restriction, any applicable securities laws and the conditions set forth in Section 4(d), this Warrant and all
rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender
of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant
substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any
transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion
of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant
in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date the Holder
delivers an assignment form to the Company assigning this Warrant full. The Warrant, if properly assigned in accordance herewith,
may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

b)
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated
the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable
pursuant thereto.

 

c)
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and
treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.

 

d)
Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a
view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable
state securities law, except pursuant to sales registered or exempted under the Securities Act.

 

    	11

    	 

    

 

Section
5. Registration Rights.

 

5.1 Demand Registration.

 

5.1.1
Grant of Right. The Company, upon written demand (a “Demand Notice”) of the Holder(s) of at least 51%
of the Warrants and/or the underlying Warrant Shares (“Majority Holders”), agrees to register, on one occasion,
all or any portion of the Warrant Shares underlying the Warrants (collectively, the “Registrable Securities”).
On such occasion, the Company will file a registration statement with the Commission covering the Registrable Securities within
thirty (30) days after receipt of a Demand Notice and use its commercially reasonable efforts to have the registration statement
declared effective promptly thereafter, subject to compliance with review by the Commission; provided, however, that the Company
shall not be required to comply with a Demand Notice if the Company has filed a registration statement with respect to which the
Holder is entitled to piggyback registration rights pursuant to Section 5.2 hereof and either: (i) the Holder has elected to participate
in the offering covered by such registration statement or (ii) if such registration statement relates to an underwritten primary
offering of securities of the Company, until the offering covered by such registration statement has been withdrawn or until thirty
(30) days after such offering is consummated. The sole demand for registration may be made at any time beginning on the Initial
Exercise Date and expiring on the fifth anniversary of the Effective Date in accordance with FINRA Rule 5110(g)(8)(C). The Company
covenants and agrees to give written notice of its receipt of any Demand Notice by any Holder(s) to all other registered Holders
of the Warrants and/or the Registrable Securities within ten (10) days after the date of the receipt of any such Demand Notice.

 

5.1.2
Terms. The Company shall bear all fees and expenses attendant to the registration of the Registrable Securities pursuant to Section
5.1.1, but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders
to represent them in connection with the sale of the Registrable Securities. The Company agrees to use its commercially reasonable
efforts to cause the filing required herein to become effective promptly and to qualify or register the Registrable Securities
in such States as are reasonably requested by the Holder(s); provided, however, that in no event shall the Company be required
to register the Registrable Securities in a State in which such registration would cause: (i) the Company to be obligated to register
or license to do business in such State or submit to general service of process in such State, or (ii) the principal stockholders
of the Company to be obligated to escrow their shares of capital stock of the Company. The Company shall cause any registration
statement filed pursuant to the demand right granted under Section 5.1.1 to remain effective for a period of at least twelve (12)
consecutive months after the date that the Holders of the Registrable Securities covered by such registration statement are first
given the opportunity to sell all of such securities. The Holders shall only use the prospectuses provided by the Company to sell
the Warrant Shares covered by such registration statement, and will immediately cease to use any prospectus furnished by the Company
if the Company advises the Holder that such prospectus may no longer be used due to a material misstatement or omission. Notwithstanding
the provisions of this Section 5.1.2, the Holder shall be entitled to a demand registration under this Section 5.1.2 on only one
(1) occasion and such demand registration right shall terminate on the fifth anniversary of the date of the Underwriting Agreement
(as defined below) in accordance with FINRA Rule 5110(g)(8)(C).

 

    	12

    	 

    

 

5.2
“Piggy-Back” Registration.

 

5.2.1
Grant of Right. In addition to the demand right of registration described in Section 5.1 hereof, the Holder shall have
the right, for a period of no more than five (5) years from the Initial Exercise Date in accordance with FINRA Rule 5110(g)(8)(D),
to include the Registrable Securities as part of any other registration of securities filed by the Company (other than in connection
with a transaction contemplated by Rule 145(a) promulgated under the Securities Act or pursuant to Form S-8 or any equivalent
form); provided, however, that if, solely in connection with any primary underwritten public offering for the account of the Company,
the managing underwriter(s) thereof shall, in its reasonable discretion, impose a limitation on the number of Registrable Securities
that may be included in the Registration Statement because, in such underwriter(s)’ judgment, marketing or other factors
dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to include in such
Registration Statement only such limited portion of the Registrable Securities with respect to which the Holder requested inclusion
hereunder as the underwriter shall reasonably permit. Any exclusion of Registrable Securities shall be made pro rata among the
Holders seeking to include Registrable Securities in proportion to the number of Registrable Securities sought to be included
by such Holders; provided, however, that the Company shall not exclude any Registrable Securities unless the Company has first
excluded all outstanding securities, the holders of which are not entitled to inclusion of such securities in such Registration
Statement or are not entitled to pro rata inclusion with the Registrable Securities.

 

5.2.2
Terms. The Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to Section
5.2.1 hereof, but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by
the Holders to represent them in connection with the sale of the Registrable Securities. In the event of such a proposed registration,
the Company shall furnish the then Holders of outstanding Registrable Securities with not less than thirty (30) days written notice
prior to the proposed date of filing of such registration statement. Such notice to the Holders shall continue to be given for
each registration statement filed by the Company during the five (5) year period following the Initial Exercise Date until such
time as all of the Registrable Securities have been sold by the Holder. The holders of the Registrable Securities shall exercise
the “piggy-back” rights provided for herein by giving written notice within ten (10) days of the receipt of the Company’s
notice of its intention to file a registration statement. Except as otherwise provided in this Warrant, there shall be no limit
on the number of times the Holder may request registration under this Section 5.2.2; provided, however, that such registration
rights shall terminate on the third anniversary of the Initial Exercise Date.

 

5.3
General Terms

 

5.3.1
Indemnification. The Company shall indemnify the Holder(s) of the Registrable Securities to be sold pursuant to any registration
statement hereunder and each person, if any, who controls such Holders within the meaning of Section 15 of the Securities Act
or Section 20 (a) of the Exchange Act against all loss, claim, damage, expense or liability (including all reasonable attorneys’
fees and other expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which any
of them may become subject under the Securities Act, the Exchange Act or otherwise, arising from such registration statement but
only to the same extent and with the same effect as the provisions pursuant to which the Company has agreed to indemnify the Underwriters
contained in Section 5.1 of the Underwriting Agreement. The Holder(s) of the Registrable Securities to be sold pursuant to such
registration statement, and their successors and assigns, shall severally, and not jointly, indemnify the Company, against all
loss, claim, damage, expense or liability (including all reasonable attorneys’ fees and other expenses reasonably incurred
in investigating, preparing or defending against any claim whatsoever) to which they may become subject under the Securities Act,
the Exchange Act or otherwise, arising from information furnished by or on behalf of such Holders, or their successors or assigns,
in writing, for specific inclusion in such registration statement to the same extent and with the same effect as the provisions
contained in Section 5.2 of the Underwriting Agreement pursuant to which the Underwriters have agreed to indemnify the Company.

 

    	13

    	 

    

 

5.3.2
Exercise of Warrants. Nothing contained in this Warrant shall be construed as requiring the Holder(s) to exercise their Warrants
prior to or after the initial filing of any registration statement or the effectiveness thereof.

 

5.3.3
Documents Delivered to Holders. The Company shall furnish to each Holder participating in any of the foregoing offerings
and to each underwriter of any such offering, if any, a signed counterpart, addressed to such Holder or underwriter, of: (i) an
opinion of counsel to the Company, dated the effective date of such registration statement (and, if such registration includes
an underwritten public offering, an opinion dated the date of the closing under any underwriting agreement related thereto), and
(ii) a “cold comfort” letter dated the effective date of such registration statement (and, if such registration includes
an underwritten public offering, a letter dated the date of the closing under the underwriting agreement) signed by the independent
registered public accounting firm which has issued a report on the Company’s financial statements included in such registration
statement, in each case covering substantially the same matters with respect to such registration statement (and the prospectus
included therein) and, in the case of such accountants’ letter, with respect to events subsequent to the date of such financial
statements, as are customarily covered in opinions of issuer’s counsel and in accountants’ letters delivered to underwriters
in underwritten public offerings of securities. The Company shall also deliver promptly to each Holder participating in the offering
requesting the correspondence and memoranda described below and to the managing underwriter, if any, copies of all correspondence
between the Commission and the Company, its counsel or auditors and all memoranda relating to discussions with the Commission
or its staff with respect to the registration statement and permit each Holder and underwriter to do such investigation, upon
reasonable advance notice, with respect to information contained in or omitted from the registration statement as it deems reasonably
necessary to comply with applicable securities laws or rules of FINRA. Such investigation shall include access to books, records
and properties and opportunities to discuss the business of the Company with its officers and independent auditors, all to such
reasonable extent and at such reasonable times as any such Holder shall reasonably request.

 

5.3.4
Underwriting Agreement. The Company shall enter into an underwriting agreement with the managing underwriter(s), if any,
selected by any Holders whose Registrable Securities are being registered pursuant to this Section 5, which managing underwriter
shall be reasonably satisfactory to the Company. Such agreement shall be reasonably satisfactory in form and substance to the
Company, each Holder and such managing underwriters, and shall contain such representations, warranties and covenants by the Company
and such other terms as are customarily contained in agreements of that type used by the managing underwriter. The Holders shall
be parties to any underwriting agreement relating to an underwritten sale of their Registrable Securities and may, at their option,
require that any or all the representations, warranties and covenants of the Company to or for the benefit of such underwriters
shall also be made to and for the benefit of such Holders. Such Holders shall not be required to make any representations or warranties
to or agreements with the Company or the underwriters except as they may relate to such Holders, their Warrant Shares and their
intended methods of distribution.

 

5.3.5
Documents to be Delivered by Holder(s). Each of the Holder(s) participating in any of the foregoing offerings shall furnish
to the Company a completed and executed questionnaire provided by the Company requesting information customarily sought of selling
security holders.

 

5.3.6
Damages. Should the registration or the effectiveness thereof required by Sections 5.1 and 5.2 hereof be delayed by the
Company or the Company otherwise fails to comply with such provisions, the Holder(s) shall, in addition to any other legal or
other relief available to the Holder(s), be entitled to obtain specific performance or other equitable (including injunctive)
relief against the threatened breach of such provisions or the continuation of any such breach, without the necessity of proving
actual damages and without the necessity of posting bond or other security.

 

    	14

    	 

    

 

Section
6. Miscellaneous.

 

	 	a)	No
    Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other
    rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i).
	 	 	 
	 	b)	Loss,
    Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
    satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any certificate relating to the Warrant
    Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
    of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
    if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
    in lieu of such Warrant or stock certificate.
	 	 	 
	 	c)	Saturdays,
    Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
    or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding
    Trading Day.
	 	 	 
	 	d)	Authorized
    Shares.

 

The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common
Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights
under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers
who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant.
The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided
herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common
Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights
represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant
Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens
and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above
the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares
upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform
its obligations under this Warrant.

 

    	15

    	 

    

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.

 

	 	e)	Jurisdiction.
    All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in
    accordance with the provisions of the Underwriting Agreement.
	 	 	 
	 	f)	Restrictions.
    The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder
    does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.
	 	 	 
	 	g)	Nonwaiver
    and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
    operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any
    other provision of this Warrant or the Underwriting Agreement, if the Company willfully and knowingly fails to comply with
    any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such
    amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’
    fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in
    otherwise enforcing any of its rights, powers or remedies hereunder.
	 	 	 
	 	h)	Notices.
    Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be
    delivered in accordance with the notice provisions of the Underwriting Agreement.
	 	 	 
	 	i)	Limitation
    of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to
    purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability
    of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted
    by the Company or by creditors of the Company.
	 	 	 
	 	j)	Remedies.
    The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
    to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
    for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
    assert the defense in any action for specific performance that a remedy at law would be adequate.

 

    	16

    	 

    

 

	 	k)	Successors
    and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
    inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
    assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this
    Warrant and shall be enforceable by the Holder or holder of Warrant Shares.
	 	 	 
	 	l)	Amendment.
    This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.
	 	 	 
	 	m)	Severability.
    Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
    law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be
    ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the
    remaining provisions of this Warrant.

 

	 	n)	Headings.
    The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part
    of this Warrant.

 

********************

 

(Signature
Page Follows)

 

    	17

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
above indicated.

 

	 	SAVE
    FOODS, Inc.
	 	 
	 	By:	             
	 	Name:	
	 	Title:	

 

    	18

    	 

    

 

NOTICE
OF EXERCISE

 

TO:
SAVE FOODS, Inc.

_________________________

 

(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.

 

(2)
Payment shall take the form of (check applicable box):

 

[  ]
in lawful money of the United States; or

 

[  ]
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise
procedure set forth in subsection 2(c).

 

(3)
Please register and issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

The
Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:

 

_______________________________

 

_______________________________

 

_______________________________

 

(4)
Accredited Investor. If the Warrant is being exercised via cash exercise, the undersigned is an “accredited investor”
as defined in Regulation D promulgated under the Securities Act of 1933, as amended

 

[SIGNATURE
OF HOLDER]

 

Name
of Investing Entity: _______________________________________________________________

 

Signature
of Authorized Signatory of Investing Entity: _________________________________________

 

Name
of Authorized Signatory: ___________________________________________________________

 

Title
of Authorized Signatory: ____________________________________________________________

 

Date:
________________________________________________________________________________

 

    	19

    	 

    

 

ASSIGNMENT
FORM

 

(To
assign the foregoing warrant, execute

this
form and supply required information.

Do
not use this form to exercise the warrant.)

 

FOR
VALUE RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned
to

 

_______________________________________________
whose address is

 

_______________________________________________________________.

 

_______________________________________________________________

 

Dated:
______________, _______

 

Holder’s
Signature: _____________________________

 

Holder’s
Address: _____________________________

 

 _____________________________

 

NOTE:
The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration
or enlargement or any change whatsoever. Officers of corporations and those acting in a fiduciary or other representative capacity
should file proper evidence of authority to assign the foregoing Warrant.

 

    	20Exhibit 10.3

 

Asset
Purchase Agreement

 

by
and between

 

Supera
Pharmaceuticals, Inc.

 

and

 

MYMD
PHARMACEUTICALS, INC.

 

Dated
as of November 11, 2020

 

    	1

     

     

TABLE OF CONTENTS

 

	 	 	 	Page
	 	 	 	 
	Article I PURCHASE AND SALE	4
	 	 	 	 
	Section 1.01	 	Purchase and Sale of Assets	4
	Section 1.02	 	Excluded Assets	6
	Section 1.03	 	Assumed Liabilities	6
	Section 1.04	 	Purchase Price	7
	Section 1.05	 	Tax Treatment	7
	Section 1.06	 	Withholding Tax	7
	Section 1.07	 	Third Party Consents	7
	 	 	 	 
	Article II CLOSING	7
	 	 	 	 
	Section 2.01	 	Closing	7
	Section 2.02	 	Closing Deliverables	8
	Section 2.03	 	Termination Prior to Closing	9
	 	 	 	 
	Article III REPRESENTATIONS AND WARRANTIES OF SELLER	9
	 	 	 	 
	Section 3.01	 	Organization and Authority of Seller	9
	Section 3.02	 	No Conflicts or Consents	9
	Section 3.03	 	Financial Statements	10
	Section 3.04	 	Undisclosed Liabilities	10
	Section 3.05	 	Absence of Certain Changes, Events, and Conditions	10
	Section 3.06	 	Assigned Contracts	10
	Section 3.07	 	Title to Purchased Assets	10
	Section 3.08	 	Legal Proceedings; Governmental Orders	10
	Section 3.09	 	Compliance with Laws	11
	Section 3.10	 	Taxes	11
	Section 3.11	 	Intellectual Property	11
	Section 3.12	 	Brokers	12
	 	 	 	 
	Article IV REPRESENTATIONS AND WARRANTIES OF BUYER	12
	 	 	 	 
	Section 4.01	 	Organization and Authority of Buyer	12
	Section 4.02	 	No Conflicts; Consents	12
	Section 4.03	 	Brokers	12
	Section 4.04	 	Legal Proceedings	13
	 	 	 	 
	Article V COVENANTS	13
	 	 	 	 
	Section 5.01	 	Confidentiality	13
	Section 5.02	 	Public Announcements	13
	Section 5.03	 	Bulk Sales Laws	13
	Section 5.04	 	Transfer Taxes	13

 

    	2

     

     

	Section 5.05	 	Conduct of Business Prior to Closing	14
	Section 5.06	 	Further Assurances	14
	 	 	 	 
	Article VI MISCELLANEOUS	14
	 	 	 	 
	Section 6.01	 	Expenses	14
	Section 6.02	 	Notices	14
	Section 6.03	 	Interpretation; Headings	15
	Section 6.04	 	Severability	15
	Section 6.05	 	Entire Agreement	15
	Section 6.06	 	Successors and Assigns	15
	Section 6.07	 	Amendment and Modification; Waiver	15
	Section 6.08	 	Governing Law; Submission to Jurisdiction	15
	Section 6.09	 	Non-Survival of Representations, Warranties	15
	Section 6.10	 	Counterparts	15

 

    	3

     

     

ASSET PURCHASE
AGREEMENT

 

This Asset Purchase Agreement
(this “Agreement”), dated as of November 11, 2020, is entered into between MYMD PHARMACEUTICALS, INC., a Florida
corporation (“Buyer”), and Supera Pharmaceuticals, Inc., a Florida
corporation (“Seller”). Capitalized terms used in this Agreement have the meanings given to such terms herein.

 

RECITALS

 

WHEREAS, Seller
is engaged in the business of developing synthetic derivatives of naturally grown cannabidiols (the “Business”);

 

WHEREAS, this Agreement
is being entered into concurrently with that certain Agreement and Plan of Merger and Reorganization between Akers Biosciences,
Inc., XYZ Merger Sub Inc., and MyMD Pharmaceuticals, Inc. (the “Merger Agreement”) that contemplates the merger,
upon the terms and conditions set forth therein, of XYZ Merger Sub Inc. with and into the Buyer (the “Akers Merger”);
and

 

WHEREAS, Seller
wishes to sell and assign to Buyer, and Buyer wishes to purchase and assume from Seller, substantially all the assets, and certain
specified liabilities, of Seller, subject to the terms and conditions set forth herein.

 

NOW, THEREFORE,
in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

Article
I

PURCHASE AND SALE

 

Section
1.01 Purchase and Sale of Assets. Subject to the terms and conditions set forth herein, at the Closing, Seller shall
sell, convey, assign, transfer, and deliver to Buyer, and Buyer shall purchase from Seller, the following assets, properties and
rights of Seller, free and clear of all Encumbrances (collectively, the “Purchased Assets”):

 

(a) all Contracts
(the “Assigned Contracts”) set forth on Section 1.01(d) of the disclosure schedules attached hereto (the
“Disclosure Schedules”). The term “Contracts” means all contracts, leases, licenses, instruments,
notes, commitments, undertakings, indentures, joint ventures, and all other agreements, commitments, and legally binding arrangements,
whether written or oral;

 

(b) all of Seller’s
rights under warranties, indemnities, and all similar rights against third parties to the extent related to any Purchased Assets;

 

(c) originals
or, where not available, copies, of all books and records, including books of account, ledgers, and general, financial, and accounting
records, machinery and equipment maintenance files, customer lists, customer purchasing histories, price lists, distribution lists,
supplier lists, production data, quality control records and procedures, customer complaints and inquiry files, research and development
files, records, and data (including all correspondence with any federal, state, local, or foreign government or political subdivision
thereof, or any agency or instrumentality of such government or political subdivision, or any arbitrator, court, or tribunal of
competent jurisdiction (collectively, “Governmental Authority”)), sales material and records, strategic plans
and marketing, and promotional surveys, material, and research (“Books and Records”);

 

    	4

     

     

(d) all Intellectual
Property that is owned by Seller, together with all (i) royalties, fees, income, payments, and other proceeds now or hereafter
due or payable to Seller with respect to such Intellectual Property; and (ii) claims and causes of action with respect to such
Intellectual Property, whether accruing before, on, or after the date hereof, including all rights to and claims for damages, restitution,
and injunctive and other legal or equitable relief for past, present, or future infringement, misappropriation, or other violation
thereof (collectively, the “Intellectual Property Assets”);

 

(e) all Technical
Information;

 

(f) any inventories
of compounds, products, supplies, equipment and other tangible assets used in connection with the Business;

 

(g) all authorizations,
consents, approvals, licenses, orders, permits and exemptions of, and filings or registrations with, any governmental authority,
to the extent transferable by the Seller;

 

(h) all goodwill
and the going concern value of the Purchased Assets, Seller and the Business; and

 

(i) all other
assets owned by Seller used or useful in the Business, whether or not reflected on the books and records of the Seller.

 

    	5

     

     

For purposes of this Agreement,
(i) “Intellectual Property” means any and all rights in, arising out of, or associated with any of the following
in any jurisdiction throughout the world: (a) issued patents and patent applications (whether provisional or non-provisional),
including divisionals, continuations, continuations-in-part, substitutions, reissues, reexaminations, extensions, or restorations
of any of the foregoing, and other Governmental Authority-issued indicia of invention ownership (including certificates of invention,
petty patents, and patent utility models) (“Patents”); (b) trademarks, service marks, brands, certification
marks, logos, trade dress, trade names, and other similar indicia of source or origin, together with the goodwill connected with
the use of and symbolized by, and all registrations, applications for registration, and renewals of, any of the foregoing (“Trademarks”);
(c) copyrights and works of authorship, whether or not copyrightable, and all registrations, applications for registration, and
renewals of any of the foregoing (“Copyrights”); (d) internet domain names and social media account or user
names (including “handles”), whether or not Trademarks, all associated web addresses, URLs, websites and web pages,
social media sites and pages, and all content and data thereon or relating thereto, whether or not Copyrights; (e) mask works,
and all registrations, applications for registration, and renewals thereof; (f) industrial designs, and all Patents, registrations,
applications for registration, and renewals thereof; (g) trade secrets, know-how, show-how, inventions (whether or not patentable),
discoveries, improvements, technology, business and technical information, databases, data compilations and collections, pharmacology
and clinical data, tools, methods, formulae, processes, techniques, and other confidential and proprietary information and all
rights therein (“Know-How”); (h) computer programs, operating systems, applications, firmware and other code,
including all source code, object code, application programming interfaces, data files, databases, protocols, specifications, and
other documentation thereof; and (i) rights of publicity; (j) all licenses, sublicenses and other agreements by or through which
other Person’s, including any Affiliate of Seller, granter Seller exclusive or non-exclusive rights or interests in any Intellectual
Property (“IP Licenses”); and (k) all other intellectual or industrial property and proprietary rights and (ii)
“Technical Information” means data and other information related to the Seller’s product candidates and/or
compounds that is necessary and useful for the further research, development, manufacture, commercialization, and/or registration
of such product candidates and/or compounds, that is owned by Seller or otherwise controlled by Seller, and that exists as of the
Closing Date, including, without limitation, correspondence with U.S. Food and Drug Administration or other governmental authorities,
clinical data, pre-clinical data, adverse event data, pharmaceutical development reports, formulations and other medical and technical
information.

 

Section
1.02 Excluded Assets. Other than the Purchased Assets subject to Section 1.01, Buyer expressly understands and
agrees that it is not purchasing or acquiring, and Seller is not selling or assigning, any other assets or properties of Seller,
and all such other assets and properties shall be excluded from the Purchased Assets (the “Excluded Assets”).

 

Section 1.03 Assumed
Liabilities.

 

(a) Subject to
the terms and conditions set forth herein, Buyer shall assume and agree to pay, perform, and discharge only the following Liabilities
of Seller (collectively, the “Assumed Liabilities”), and no other Liabilities:

 

(i) all trade accounts
payable of Seller to third parties incurred in the ordinary course of business consistent with past practices of Seller and that
remain unpaid and are not delinquent as of the Closing Date; and

 

(ii) all Liabilities
in respect of the Assigned Contracts but only to the extent that such Liabilities thereunder are required to be performed after
the Closing Date, were incurred in the ordinary course of business, and do not relate to any failure to perform, improper performance,
warranty, or other breach, default, or violation by Seller on or prior to the Closing.

 

For purposes of this Agreement,
“Liabilities” means liabilities, obligations, or commitments of any nature whatsoever, whether asserted or unasserted,
known or unknown, absolute or contingent, accrued or unaccrued, matured or unmatured, or otherwise.

 

    	6

     

     

(b) Notwithstanding
any provision in this Agreement to the contrary, Buyer shall not assume and shall not be responsible to pay, perform, or discharge
any Liabilities of Seller or any of its Affiliates of any kind or nature whatsoever other than the Assumed Liabilities (the “Excluded
Liabilities”). For purposes of this Agreement: (i) “Affiliate” of a Person means any other Person
that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such
Person; and (ii) the term “control” (including the terms “controlled by” and “under common
control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management
and policies of a Person, whether through the ownership of voting securities, by contract, or otherwise.

 

Section 1.04 Purchase
Price. The aggregate purchase price (the “Purchase Price”)
for the Purchased Assets shall be 33,937,909 shares of the common stock, par value $.001 per share, of Buyer (the “Purchase
Shares”), plus the assumption of the Assumed Liabilities.

 

Section 1.05 Tax Treatment.
For US federal income tax purposes, the parties intend that the Merger qualify as a tax-free
reorganization within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended. Buyer and Seller shall file
all returns, declarations, reports, information returns and statements, and other documents relating to Taxes (including amended
returns and claims for refund) (“Tax Returns”) in a manner consistent with the foregoing intention of the Parties.

 

Section 1.06 Withholding
Tax. Buyer shall be entitled to deduct and withhold from the Purchase Price all Taxes that
Buyer may be required to deduct and withhold under any provision of Tax Law. All such withheld amounts shall be treated as delivered
to Seller hereunder.

 

Section 1.07 Third Party
Consents. To the extent that Seller’s rights under any Purchased Asset may not be assigned
to Buyer without the consent of another Person which has not been obtained, this Agreement shall not constitute an agreement to
assign the same if an attempted assignment would constitute a breach thereof or be unlawful, and Seller, at its expense, shall
use its reasonable best efforts to obtain any such required consent(s) as promptly as possible. If any such consent shall not be
obtained or if any attempted assignment would be ineffective or would impair Buyer’s rights under the Purchased Asset in
question so that Buyer would not in effect acquire the benefit of all such rights, Seller, to the maximum extent permitted by Law
and the Purchased Asset, shall act after the Closing as Buyer’s agent in order to obtain for it the benefits thereunder and
shall cooperate, to the maximum extent permitted by Law and the Purchased Asset, with Buyer in any other reasonable arrangement
designed to provide such benefits to Buyer.

 

Article
II

CLOSING

 

Section 2.01 Closing.
Subject to the terms and conditions of this Agreement, the consummation of the transactions contemplated by this Agreement
(the “Closing”) shall take place at the offices of Foley & Lardner LLP, 100 North Tampa St., Suite 2700,
Tampa, Florida 33602, immediately prior to (and contingent on) the closing of the Akers Merger, or at such other time or place
or in such other manner as Seller and Buyer may mutually agree upon in writing. The date on which the Closing is to occur is herein
referred to as the “Closing Date.”

 

    	7

     

     

Section 2.02 Closing
Deliverables.

 

(a) At the Closing,
Seller shall deliver to Buyer the following:

 

(i) a bill of sale
in form and substance satisfactory to Buyer (the “Bill of Sale”) and duly executed by Seller, transferring the
Tangible Personal Property included in the Purchased Assets to Buyer;

 

(ii) an assignment
and assumption agreement in form and substance satisfactory to Buyer (the “Assignment and Assumption Agreement”)
and duly executed by Seller, effecting the assignment to and assumption by Buyer of the Purchased Assets and the Assumed Liabilities;

 

(iii) an assignment
in form and substance satisfactory to Buyer (the “Intellectual Property Assignment”) and duly executed by Seller,
transferring all of Seller’s right, title and interest in and to the Intellectual Property Assets to Buyer;

 

(iv) a certificate
of the Secretary (or equivalent officer) of Seller certifying as to (A) the resolutions of the board of directors and the shareholders
of Seller, which authorize the execution, delivery, and performance of this Agreement, the Bill of Sale, the Assignment and Assumption
Agreement, the Intellectual Property Assignment and the other agreements, instruments, and documents required to be delivered in
connection with this Agreement or at the Closing (collectively, the “Transaction Documents”) and the consummation
of the transactions contemplated hereby and thereby, and (B) the names and signatures of the officers of Seller authorized to sign
this Agreement and the other Transaction Documents; and

 

(v) such other
customary instruments of transfer or assumption, filings, or documents, in form and substance reasonably satisfactory to Buyer,
as may be required to give effect to the transactions contemplated by this Agreement.

 

(b) At the Closing,
Buyer shall deliver to Seller the following:

 

(i) a stock certificate
evidencing the Purchase Shares, duly endorsed in blank or accompanied by a stock power or other instrument of transfer (less any
amounts which may be withheld for outstanding Tax Liabilities);

 

(ii) the Intellectual
Property Assignment duly executed by Buyer; and

 

(iii) a certificate
of the Secretary (or equivalent officer) of Buyer certifying as to (A) the resolutions of the board of directors of Buyer, which
authorize the execution, delivery, and performance of this Agreement and the Transaction Documents and the consummation of the
transactions contemplated hereby and thereby, and (B) the names and signatures of the officers of Buyer authorized to sign this
Agreement and the other Transaction Documents.

 

    	8

     

     

Section 2.03 Termination
Prior to Closing.

 

(a) This Agreement
and the transactions contemplated hereby shall automatically and immediately terminate upon the termination of the Merger Agreement,
regardless of the reason for the termination of the Merger Agreement.

 

In the event of a termination
of this Agreement under this Section 2.03, this Agreement shall forthwith become void and of no further force or effect
and there shall be no liability or obligation on the part of any party hereto.

 

Article
III

REPRESENTATIONS AND WARRANTIES OF SELLER

 

Seller represents and warrants
to Buyer that the statements contained in this Article III are true and correct as of the date hereof.

 

Section 3.01 Organization
and Authority of Seller. Seller is a corporation duly organized, validly existing, and in
good standing under the Laws of the State of Florida. Seller has full corporate power and authority to enter into this Agreement
and the other Transaction Documents to which Seller is a party, to carry out its obligations hereunder and thereunder, and to consummate
the transactions contemplated hereby and thereby. The execution and delivery by Seller of this Agreement and any other Transaction
Document to which Seller is a party, the performance by Seller of its obligations hereunder and thereunder, and the consummation
by Seller of the transactions contemplated hereby and thereby have been duly authorized by all requisite corporate, board, and
shareholder action on the part of Seller. This Agreement and the Transaction Documents constitute legal, valid, and binding obligations
of Seller enforceable against Seller in accordance with their respective terms.

 

Section 3.02 No Conflicts
or Consents. The execution, delivery, and performance by Seller of this Agreement and the
other Transaction Documents to which it is a party, and the consummation of the transactions contemplated hereby and thereby, do
not and will not: (a) violate or conflict with any provision of the certificate of formation, bylaws, or other governing documents
of Seller; (b) violate or conflict with any provision of any statute, law, ordinance, regulation, rule, code, constitution, treaty,
common law, other requirement, or rule of law of any Governmental Authority (collectively, “Law”)
or any order, writ, judgment, injunction, decree, stipulation, determination, penalty, or award entered by or with any Governmental
Authority (“Governmental Order”) applicable to Seller or the Purchased
Assets; (c) require the consent, notice, declaration, or filing with or other action by any individual, corporation, partnership,
joint venture, limited liability company, Governmental Authority, unincorporated organization, trust, association, or other entity
(“Person”) or require any permit, license, or Governmental Order; (d)
violate or conflict with, result in the acceleration of, or create in any party the right to accelerate, terminate, modify, or
cancel any Contract to which Seller is a party or by which Seller is bound or to which any of the Purchased Assets are subject
(including any Assigned Contract); or (e) result in the creation or imposition of any charge, claim, pledge, equitable interest,
lien, security interest, restriction of any kind, or other encumbrance (“Encumbrance”)
on the Purchased Assets.

 

    	9

     

     

Section
3.03 Financial Statements. Complete copies of the unaudited financial statements consisting
of the balance sheet of Seller as at December 31, 2020 and June 30, 2020 and the related statements of income and retained earnings,
shareholders’ equity, and cash flow for the year and 6-month period, respectively, then ended (the “Financial
Statements”) have been delivered to Buyer. The Financial Statements have been prepared in accordance with generally accepted
accounting principles in effect in the United States from time to time, applied on a consistent basis throughout the period involved.
The Financial Statements fairly present the financial condition of Seller as of the respective dates they were prepared and the
results of the operations of Seller for the periods indicated. The balance sheet of Seller as of June 30, 2020 is referred to herein
as the “Balance Sheet” and the date thereof as the “Balance
Sheet Date”.

 

Section 3.04 Undisclosed
Liabilities. Seller has no Liabilities, except (a) those which are adequately reflected or
reserved against in the Balance Sheet as of the Balance Sheet Date, and (b) those which have been incurred in the ordinary course
of business consistent with past practice since the Balance Sheet Date and which are not, individually or in the aggregate, material
in amount.

 

Section 3.05 Absence
of Certain Changes, Events, and Conditions. Since the Balance Sheet Date, and other than
in the ordinary course of business consistent with past practice, there has not been any change, event, condition, or development
that is, or could reasonably be expected to be, individually or in the aggregate, materially adverse to: (a) the business, results
of operations, condition (financial or otherwise), or assets of Seller; or (b) the value of the Purchased Assets.

 

Section 3.06 Assigned
Contracts. Each Assigned Contract is valid and binding on Seller in accordance with its terms
and is in full force and effect. Neither Seller nor, to Seller’s knowledge, any other party thereto is in breach of or default
under (or is alleged to be in breach of or default under), or has provided or received any notice of any intention to terminate,
any Assigned Contract. No event or circumstance has occurred that would constitute an event of default under any Assigned Contract
or result in a termination thereof. Complete and correct copies of each Assigned Contract (including all modifications, amendments,
and supplements thereto and waivers thereunder) have been made available to Buyer. There are no disputes pending or threatened
under any Assigned Contract.

 

Section 3.07 Title
to Purchased Assets. Seller has good and valid title to all of the Purchased Assets, free and
clear of Encumbrances.

 

Section 3.08 Legal
Proceedings; Governmental Orders.

 

(a) There are
no claims, actions, causes of action, demands, lawsuits, arbitrations, inquiries, audits, notices of violation, proceedings, litigation,
citations, summons, subpoenas, or investigations of any nature, whether at law or in equity (collectively, “Actions”)
pending or, to Seller’s knowledge, threatened against or by Seller: (a) relating to or affecting Seller, the Purchased Assets,
or the Assumed Liabilities; or (b) that challenge or seek to prevent, enjoin, or otherwise delay the transactions contemplated
by this Agreement. No event has occurred or circumstances exist that may give rise to, or serve as a basis for, any such Action.

 

    	10

     

     

(b) There are
no outstanding Governmental Orders against, relating to, or affecting Seller or the Purchased Assets.

 

Section 3.09 Compliance
with Laws. Seller is in compliance with all Laws applicable to the conduct of the Business as
currently conducted or the ownership and use of the Purchased Assets. The Purchased Assets are all of the assets used in the Business.

 

Section 3.10 Taxes.
All Taxes due and owing by Seller have been, or will be, timely paid. No extensions or waivers of statutes of limitations have
been given or requested with respect to any Taxes of Seller. All Tax Returns required to be filed by Seller for any tax periods
prior to Closing have been, or will be, timely filed. Such Tax Returns are, or will be, true, complete, and correct in all respects.
The term “Taxes” means all federal, state, local, foreign, and other income,
gross receipts, sales, use, production, ad valorem, transfer, documentary, franchise, registration, profits, license, withholding,
payroll, employment, unemployment, excise, severance, stamp, occupation, premium, property (real or personal), customs, duties,
or other taxes, fees, assessments, or charges of any kind whatsoever, together with any interest, additions, or penalties with
respect thereto.

 

Section 3.11 Intellectual
Property.

 

(a) Section
3.11(a) of the Disclosure Schedules lists (i) all Intellectual Property Assets and (ii) all IP Licenses all licenses, sublicenses
and other agreements by or through which other Persons grant Seller or Seller grants any other Persons any exclusive or non-exclusive
rights or interests in or to any Intellectual Property (excluding shrink-wrap, click-wrap, or other similar agreements for commercially
available off-the-shelf software). Seller is the exclusive owner of the Intellectual Property Assets, free and clear of all Encumbrances.
The Intellectual Property Assets together with the Intellectual Property licensed to Seller pursuant to the IP Licenses constitutes
all of the material Intellectual Property Rights used or held for use by the Seller in conducting the Business. Immediately after
the Closing, Buyer will own all of the Intellectual Property Assets and will have a right to use all of the Intellectual Property
licensed to Seller, free from any Encumbrances and on the same terms and conditions as in effect prior to the Closing.

 

(b) The conduct
of the Business as currently conducted does not infringe, misappropriate, dilute or otherwise violate the Intellectual Property
of any Person and no Person is infringing, misappropriating or otherwise violating any Intellectual Property Assets. Notwithstanding
anything to the contrary in this Agreement, this Section 3.11(b) constitutes the sole representation and warranty of Seller
under this Agreement with respect to any actual or alleged infringement, misappropriation or other violation by Seller of any Intellectual
Property of any other Person.

 

(c) Schedule
3.11(c) sets forth all contracts to which Seller is a party or is otherwise bound that relate to Intellectual Property used or
held for use in the Business, including: (i) the IP Licenses; (ii) licenses of Intellectual Property to any other Person by Seller;
(iii) contracts otherwise granting or restricting the right to use any Intellectual Property; and (iv) Contracts transferring,
assigning, indemnifying with respect to or otherwise relating to Intellectual Property.

 

    	11

     

     

(d) Seller has
taken all actions reasonably necessary to make or maintain in full force and effect all necessary filings, registrations and issuances
in respect thereof necessary to maintain the Seller’s ownership rights in the Intellectual Property Assets, and such filings,
registrations and issuances are valid and enforceable. Seller has taken all actions reasonably necessary to maintain the secrecy
of all confidential Intellectual Property, including Know-How and Technical Information, used in the Business. Seller is not using
or enforcing any of the Seller’s rights in material Intellectual Property Assets or Intellectual Property licensed to Seller
in a manner that would reasonably be expected to result in the cancellation, invalidity or unenforceability thereof.

 

Section 3.12 Brokers.
No broker, finder, or investment banker is entitled to any brokerage, finder’s, or other fee or commission in connection
with the transactions contemplated by this Agreement or any other Transaction Document based upon arrangements made by or on behalf
of Seller.

 

Article
IV

REPRESENTATIONS AND WARRANTIES OF BUYER

 

Buyer represents and warrants
to Seller that the statements contained in this Article IV are true and correct as of the date hereof.

 

Section 4.01 Organization
and Authority of Buyer. Buyer is a corporation duly organized, validly existing, and in good
standing under the Laws of the State of Florida. Buyer has full corporate power and authority to enter into this Agreement and
the other Transaction Documents to which Buyer is a party, to carry out its obligations hereunder and thereunder, and to consummate
the transactions contemplated hereby and thereby. The execution and delivery by Buyer of this Agreement and any other Transaction
Document to which Buyer is a party, the performance by Buyer of its obligations hereunder and thereunder, and the consummation
by Buyer of the transactions contemplated hereby and thereby have been duly authorized by all requisite corporate action on the
part of Buyer. This Agreement and the Transaction Documents constitute legal, valid, and binding obligations of Buyer enforceable
against Buyer in accordance with their respective terms.

 

Section 4.02 No Conflicts;
Consents. The execution, delivery, and performance by Buyer of this Agreement and the other Transaction
Documents to which it is a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not:
(a) violate or conflict with any provision of the certificate of formation, bylaws, or other organizational documents of Buyer;
(b) violate or conflict with any provision of any Law or Governmental Order applicable to Buyer; or (c) require the consent, notice,
declaration, or filing with or other action by any Person or require any permit, license, or Governmental Order.

 

Section 4.03 Brokers.
No broker, finder, or investment banker is entitled to any brokerage, finder’s, or other fee or commission in connection
with the transactions contemplated by this Agreement or any other Transaction Document based upon arrangements made by or on behalf
of Buyer.

 

    	12

     

     

Section 4.04 Legal
Proceedings. There are no Actions pending or, to Buyer’s knowledge, threatened against
or by Buyer that challenge or seek to prevent, enjoin, or otherwise delay the transactions contemplated by this Agreement. No event
has occurred or circumstances exist that may give rise to, or serve as a basis for, any such Action.

 

Article
V

COVENANTS

 

Section 5.01 Confidentiality.
From and after the Closing, Seller shall, and shall cause its Affiliates to, hold, and shall cause its or their respective directors,
officers, employees, consultants, counsel, accountants, and other agents (“Representatives”)
to hold, in confidence any and all information, whether written or oral, concerning Seller, the Purchased Assets or the Business,
except to the extent that Seller can show that such information: (a) is generally available to and known by the public through
no fault of Seller, any of its Affiliates, or their respective Representatives; or (b) is lawfully acquired by Seller, any of its
Affiliates, or their respective Representatives from and after the Closing from sources which are not prohibited from disclosing
such information by a legal, contractual, or fiduciary obligation. If Seller or any of its Affiliates or their respective Representatives
are compelled to disclose any information by Governmental Order or Law, Seller shall promptly notify Buyer in writing and shall
disclose only that portion of such information which is legally required to be disclosed, provided that Seller shall use
reasonable best efforts to obtain as promptly as possible an appropriate protective order or other reasonable assurance that confidential
treatment will be accorded such information.

 

Section 5.02 Public
Announcements. Unless otherwise required by applicable Law, no party to this Agreement shall
make any public announcements in respect of this Agreement or the transactions contemplated hereby without the prior written consent
of the other party (which consent shall not be unreasonably withheld or delayed), and the parties shall cooperate as to the timing
and contents of any such announcement. Notwithstanding the foregoing, Seller consents to the disclosure of this Agreement and the
transactions contemplated hereby by Akers in connection with any filings made by Akers with the U.S. Securities and Exchange Commission
in connection with the Akers Merger.

 

Section 5.03 Bulk
Sales Laws. The parties hereby waive compliance with the provisions of any bulk sales, bulk transfer,
or similar Laws of any jurisdiction that may otherwise be applicable with respect to the sale of any or all of the Purchased Assets
to Buyer. Any Liabilities arising out of the failure of Seller to comply with the requirements and provisions of any bulk sales,
bulk transfer, or similar Laws of any jurisdiction which would not otherwise constitute Assumed Liabilities shall be treated as
Excluded Liabilities.

 

Section 5.04 Transfer
Taxes. All sales, use, registration, and other such Taxes and fees (including any penalties and
interest) incurred in connection with this Agreement and the other Transaction Documents, if any, shall be borne and paid by Seller
when due. Seller shall, at its own expense, timely file any Tax Return or other document with respect to such Taxes or fees (and
Buyer shall cooperate with respect thereto as necessary).

 

    	13

     

     

Section 5.05 Conduct
of Business Prior to Closing Date. Seller covenants and agrees with Buyer that from the date
hereof hereof through the Closing Date, except as otherwise expressly contemplated in this Agreement, unless Buyer otherwise consents
in writing (which consent may be withheld Buyer’s sole discretion), Seller shall:

 

(a) Operate the
Business in all material respects in the ordinary course of business and consistent with past practice.

 

(b) Timely comply
in all material respects with the Assigned Contracts.

 

(c) Not sell,
lease, grant any rights in or to or otherwise dispose of or otherwise relinquish control of, or agree to sell, lease or otherwise
dispose of, the Purchased Assets.

 

(d) Not cause
any of the Purchased Assets to be encumbered by any Encumbrances not in existence as of the date hereof that will not be satisfied
as of the Closing Date.

 

Section 5.06 Further
Assurances. Following the Closing, each of the parties hereto shall, and shall cause their respective
Affiliates to, execute and deliver such additional documents, instruments, conveyances, and assurances and take such further actions
as may be reasonably required to carry out the provisions hereof and give effect to the transactions contemplated by this Agreement
and the other Transaction Documents.

 

Article
VI

MISCELLANEOUS

 

Section 6.01 Expenses.
All costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the
party incurring such costs and expenses.

 

Section 6.02 Notices.
All notices, claims, demands, and other communications hereunder shall be in writing and shall be deemed to have been given: (a)
when delivered by hand (with written confirmation of receipt); (b) when received by the addressee if sent by a nationally recognized
overnight courier (receipt requested); (c) on the date sent by email of a PDF document (with confirmation of transmission) if sent
during normal business hours of the recipient, and on the next business day if sent after normal business hours of the recipient,
or (d) on the third day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such
communications must be sent to the respective parties at the following addresses (or at such other address for a party as shall
be specified in a notice given in accordance with this Section 7.02):

 

	If to Seller:	Supera Pharmaceuticals, Inc.
	 	324 S. Hyde Park Ave
	 	Tampa, FL 33606
	 	Attn: James A. McNulty
	 	E-mail: jamcnulty@mymd.com

 

    	14

     

     

	If to Buyer:	MYMD Pharmaceuticals, Inc.
	 	324 S. Hyde Park Ave
	 	Tampa, FL 33606
	 	Attn: James A. McNulty
	 	E-mail: jamcnulty@mymd.com

 

Section 6.03 Interpretation;
Headings. This Agreement shall be construed without regard to any presumption or rule requiring
construction or interpretation against the party drafting an instrument or causing any instrument to be drafted. The headings in
this Agreement are for reference only and shall not affect the interpretation of this Agreement.

 

Section 6.04 Severability.
If any term or provision of this Agreement is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality,
or unenforceability shall not affect any other term or provision of this Agreement.

 

Section 6.05 Entire
Agreement. This Agreement and the other Transaction Documents constitute the sole and entire
agreement of the parties to this Agreement with respect to the subject matter contained herein and therein, and supersede all prior
and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter. In the event of
any inconsistency between the statements in the body of this Agreement and those in the other Transaction Documents, the Exhibits,
and the Disclosure Schedules (other than an exception expressly set forth as such in the Disclosure Schedules), the statements
in the body of this Agreement will control.

 

Section 6.06 Successors
and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the parties
hereto and their respective successors and permitted assigns. Neither party may assign its rights or obligations hereunder without
the prior written consent of the other party, which consent shall not be unreasonably withheld or delayed. Any purported assignment
in violation of this Section shall be null and void. No assignment shall relieve the assigning party of any of its obligations
hereunder.

 

Section 6.07 Amendment
and Modification; Waiver. This Agreement may only be amended, modified, or supplemented by an
agreement in writing signed by each party hereto. No waiver by any party of any of the provisions hereof shall be effective unless
explicitly set forth in writing and signed by the party so waiving. No failure to exercise, or delay in exercising, any right or
remedy arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise
of any right or remedy hereunder preclude any other or further exercise thereof or the exercise of any other right or remedy. Akers
is an express third party beneficiary of this Agreement and no amendment shall be made to this Agreement without the prior written
consent of Akers.

 

Section 6.08 Governing
Law; Submission to Jurisdiction. All matters arising out of or relating to this Agreement shall
be governed by and construed in accordance with the internal laws of the State of Florida without giving effect to any choice or
conflict of law provision or rule (whether of the State of Florida or any other jurisdiction). Any legal suit, action, proceeding,
or dispute arising out of or related to this Agreement, the other Transaction Documents, or the transactions contemplated hereby
or thereby may be instituted in the federal courts of the United States of America or the courts of the State of Florida in each
case located in the city of Tampa and county of Hillsborough County, and each party irrevocably submits to the exclusive jurisdiction
of such courts in any such suit, action, proceeding, or dispute.

 

Section 6.09 Non-Survival
of Representations, Warranties. The representations and warranties of Seller and Buyer contained
in this Agreement or any certificate or instrument delivered pursuant to this Agreement shall terminate at Closing, and only the
covenants that by their terms survive Closing and this Article VI shall survive Closing.

 

Section 6.10 Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed
to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, email, or other means of electronic transmission
shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

 

[Signature Page to Follow]

 

    	15

     

     

IN WITNESS WHEREOF, the parties hereto have
caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.

 

	 	Supera Pharmaceuticals, Inc.
	 	 
	 	By:	/s/ William McNulty
	 	Name:	William McNulty
	 	Title:	VP
	 	 
	 	MYMD Pharmaceuticals, Inc.
	 	 
	 	By:	/s/ James A. McNulty
	 	Name:	James A. McNulty
	 	Title:	CEO

 

    	16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]